Medical Device Nonvisual Accessibility Act of 2025

The Medical Device Nonvisual Accessibility Act of 2025 (HR5605) establishes new nonvisual accessibility standards for medical devices with digital interfaces under the Federal Food, Drug, and Cosmetic Act. This bill requires manufacturers to design devices that are usable by individuals who are blind or have low-vision, either through integrated nonvisual access technology or compatibility with existing screen access software. This is not a funding bill; it is a regulatory mandate that directly impacts product design and development for medical device manufacturers. The bill's referral to the House Committee on Energy and Commerce, with a bipartisan group of 17 cosponsors including Rep. Schakowsky (D-IL-9), indicates moderate legislative momentum. The money trail for this bill is indirect, focusing on compliance costs and new market opportunities. Medical device manufacturers must invest in R&D to redesign existing products and incorporate accessibility features into new ones. This creates a new market for specialized accessibility technology providers, although no specific companies are named in the bill. Companies like Google ($GOOGL), Microsoft ($MSFT), and Apple ($AAPL) that develop widely used screen access technologies (e.g., TalkBack, Narrator, VoiceOver) will see increased integration of their software with medical devices, expanding their ecosystem reach. The primary financial impact on medical device companies will be increased R&D and manufacturing costs in the short term, offset by an expanded customer base and avoidance of non-compliance penalties in the long term. Historically, similar mandates for accessibility have driven innovation and market expansion. For example, the Americans with Disabilities Act (ADA) of 1990, while broader, led to significant changes in public infrastructure and digital interfaces, creating new industries for accessible design. While direct market data for a medical device-specific accessibility mandate is limited, the general trend is that companies that adapt early gain market share. For instance, when Section 508 of the Rehabilitation Act was updated in 2017 to include modern ICT, companies providing accessible software solutions saw increased demand. This bill is specific to medical devices, a sector with high regulatory barriers and long product development cycles. Specific winners include companies that can rapidly integrate nonvisual accessibility into their product lines. Medical device manufacturers like Medtronic ($MDT), Intuitive Surgical ($ISRG), Abbott Laboratories ($ABT), Johnson & Johnson ($JNJ), and GE HealthCare ($GEHC) will incur initial costs for redesign and compliance but will ultimately benefit from an expanded market for their products. Companies specializing in assistive technology or offering consulting services for accessible design will also see increased demand. Losers are manufacturers that fail to adapt, risking market exclusion and potential regulatory penalties. The bill explicitly states that compatibility should be considered at the beginning of the design process, favoring companies with agile R&D. This bill is currently in the House Committee on Energy and Commerce. The next steps involve committee hearings, potential amendments, and a committee vote. If passed by the committee, it moves to the full House for a vote. If passed by the House, it goes to the Senate. The timeline for passage is uncertain but typically takes months to years for significant regulatory bills. If enacted, manufacturers will likely be given a grace period to comply, typically 1-3 years, before the standards become fully enforceable.